版本:
中国

BRIEF-Neurotrope announces positive top-line results from Phase 2 study of Bryostatin-1

May 1 Neurotrope Inc :

* Neurotrope announces positive top-line results from Phase 2 study of Bryostatin-1 for moderate to severe Alzheimer’S disease

* Results indicate 20 μg dose,administered every 2 weeks,met pre-specified primary endpoint in Completer population, not in mITT population

* Data indicate that Bryostatin-1 improves cognition and ability to perform activities of daily living

* Plans to meet with FDA to address clinical and regulatory path forward for Bryostatin-1 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐